|
|
Previous Article | Table of Contents | Next Article 
Involvement of Interleukin-3 in Delayed-Type Hypersensitivity
Nicolas Mach,
Chris S. Lantz,
Stephen J. Galli,
Glen Reznikoff,
Martin Mihm,
Clayton Small,
Richard Granstein,
Stefan Beissert,
Michel Sadelain,
Richard C. Mulligan, and
Glenn Dranoff
From the Departments of Medicine, Dana-Farber Cancer Institute and
Harvard Medical School; the Departments of Pathology, Beth Israel
Deaconess Medical and Harvard Medical School; the Departments of
Pathology, Massachusetts General Hospital and Harvard Medical School;
Howard Hughes Medical Institute, Children's Hospital, and the
Department of Genetics, Harvard Medical School, Boston, MA; the
Department of Dermatology, Cornell University Medical College, New
York, NY; the Department of Dermatology, University of Munster,
Munster, Germany; and the Department of Human Genetics and Immunology
Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
The in vivo functions of interleukin-3 (IL-3) were investigated by
generating IL-3-deficient mice. Although hematopoiesis was unimpaired
in homozygous mutant animals, contact hypersensitivity reactions were
compromised. IL-3 was required for efficient priming of hapten-specific
contact hypersensitivity responses, but was dispensable for
T-cell-dependent sensitization to tumor cells. These findings reveal a
critical role for IL-3 in some forms of delayed-type hypersensitivity.
Blood, Vol. 91 No. 3 (February 1), 1998:
pp. 778-783
© 1998 by The American Society of Hematology.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Shen, S. Kim, J.-s. Do, L. Wang, C. Lantz, J. F. Urban, G. Le Gros, and B. Min
T cell-derived IL-3 plays key role in parasite infection-induced basophil production but is dispensable for in vivo basophil survival
Int. Immunol.,
September 1, 2008;
20(9):
1201 - 1209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Enzler, S. Gillessen, M. Dougan, J. P. Allison, D. Neuberg, D. A. Oble, M. Mihm, and G. Dranoff
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of {beta} cells
Blood,
August 1, 2007;
110(3):
954 - 961.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, E. Ng, C. Yip, W. Eisterer, Y. Chalandon, M. Stuible, A. Eaves, and C. J. Eaves
Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo
Blood,
November 15, 2002;
100(10):
3731 - 3740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Jegalian, A. Acurio, G. Dranoff, and H. Wu
Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3
Blood,
April 1, 2002;
99(7):
2603 - 2605.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Wang, C. Feliciani, I. Freed, Q. Cai, and D. N. Sauder
Insights into molecular mechanisms of contact hypersensitivity gained from gene knockout studies
J. Leukoc. Biol.,
August 1, 2001;
70(2):
185 - 191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Li, S. Gillessen, M. H. Tomasson, G. Dranoff, D. G. Gilliland, and R. A. Van Etten
Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL
Blood,
March 1, 2001;
97(5):
1442 - 1450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gillessen, N. Mach, C. Small, M. Mihm, and G. Dranoff
Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity
Blood,
February 15, 2001;
97(4):
922 - 928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gainsford, H. Nandurkar, D. Metcalf, L. Robb, C. G. Begley, and W. S. Alexander
The residual megakaryocyte and platelet production in c-Mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor
Blood,
January 15, 2000;
95(2):
528 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|